As sports nutrition evolves beyond traditional supplements, businesses must consider patents, freedom to operate and wider IP strategies to protect innovation, support growth and attract investment.
The UK Government has outlined plans to reform the UK designs framework, introducing targeted examination, stronger digital design protection and measures to simplify design rights.
The UK’s new clinical trial regulations streamline approvals, strengthen transparency requirements and create important considerations for patent and IP strategies.
Where should life sciences companies file patents? Explore the commercial and legal factors that shape filing strategies, from market size and enforcement to patentability and exclusivity.
The High Court’s decision in Parabolica v Tesla confirms that the original EUTM filing date is the relevant date for assessing absolute grounds under the Brexit transitional regime.
Discover the key patent challenges facing agrochemical innovators in Europe, from inventive step and synergy data to SPCs, UPC strategy, formulations and freedom-to-operate considerations.
In Omnia v Sidel, the UPC Court of Appeal confirmed proceedings can be brought before a European patent is granted, reinforcing the need to file UPC opt-outs soon after publication.
As consumers increasingly choose skincare based on ingredients like retinol and niacinamide, companies may need to rethink patent strategies, placing greater emphasis on manufacturing innovation.
The enhanced UK-Switzerland FTA provides greater certainty on IP rights and exclusivity, supports cross-border collaboration and investment and streamlines talent mobility for pharma and biotech innovators.
A patent does not automatically grant the right to commercialise. Discover how competitor patent watching helps deep-tech businesses identify risks, monitor rivals and prepare for future freedom-to-operate reviews.
